[Asia Economy Reporter Hyungsoo Park] The major U.S. investment bank Cantor Fitzgerald has predicted a steep revenue growth curve for Nanox.


On the 29th, according to Cantor Fitzgerald, Nanox is expected to export 15,000 units of its groundbreaking medical imaging products by 2024. It is projected to generate up to $900 million in revenue by 2026. Nanox's target stock price was set at $70 per share.


Cantor Fitzgerald, one of the leading U.S. investment banks, analyzed Nanox Imaging, an Israel-based medical imaging company founded by CEO Ran Poliakine.


On December 3rd, Nanox demonstrated a new and innovative product at the 2020 North American Radiology Society (RSNA) conference. They held an online webinar with real-time commentary from radiology and medical experts. 11,000 people interested in Nanox technology participated.


During the RSNA webinar, clinical application footage of the real-time Nanox.Arc system was broadcast. Many in the radiology community expect Nanox’s invention to solve unmet challenges in digital medical imaging.



Nanox’s X-ray tubes are made with ceramic coating, costing only $100 each. In some markets, glass X-ray tubes cost $150,000, making Nanox’s pricing revolutionary. By introducing the digital era of X-rays, Nanox can provide a series of medical imaging services to patients quickly and at reasonable costs.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing